10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades

Q: Were Shehnaaz Suliman’s 10x Genomics (TXG) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the transaction was effected pursuant to Shehnaaz Suliman’s Rule 10b5-1 trading plan adopted on March 13, 2026, indicating the sales were pre-arranged rather than discretionary market-timing trades.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. director Shehnaaz Suliman reported selling a total of 5,723 shares of Class A Common Stock in open-market transactions. The sales occurred on June 16, 2026 at weighted average prices of $32.5890 and $33.2738 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,723 shares ($186,756)

Net Sell 2 txns

Insider SULIMAN SHEHNAAZ

Role null

Sold 5,723 shs ($187K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	5,359	$32.589	$175K
Sale	Class A Common Stock	364	$33.2738	$12K

Holdings After Transaction: Class A Common Stock — 32,086 shares (Direct, null)

Footnotes (1)

The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026. This transaction was executed in multiple trades at prices ranging from $32.03 to $33.02, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $33.03 to $33.49, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Total shares sold: 5,723 shares First trade size: 5,359 shares Second trade size: 364 shares +2 more

5 metrics

Total shares sold 5,723 shares Aggregate open-market sales on June 16, 2026

First trade size 5,359 shares Class A Common Stock sold at $32.5890 weighted average

Second trade size 364 shares Class A Common Stock sold at $33.2738 weighted average

Weighted average price (large block) $32.5890 per share Open-market sale on June 16, 2026

Weighted average price (small block) $33.2738 per share Open-market sale on June 16, 2026

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, Class A Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for Class A Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SULIMAN SHEHNAAZ

(Last)

(First)

(Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/16/2026		S⁽¹⁾		5,359	D	$32.589⁽²⁾	32,086	D
Class A Common Stock	06/16/2026		S⁽¹⁾		364	D	$33.2738⁽³⁾	31,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2026.

2. This transaction was executed in multiple trades at prices ranging from $32.03 to $33.02, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $33.03 to $33.49, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for Shehnaaz Suliman	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did 10x Genomics (TXG) director Shehnaaz Suliman report?

Director Shehnaaz Suliman reported selling 5,723 shares of 10x Genomics Class A Common Stock. The transactions were open-market sales executed on June 16, 2026, and disclosed in a Form 4 insider filing submitted to the SEC for regulatory transparency.

How many 10x Genomics (TXG) shares did Shehnaaz Suliman sell and at what prices?

Shehnaaz Suliman sold 5,723 shares of 10x Genomics Class A Common Stock. One trade covered 5,359 shares at a weighted average price of $32.5890, and another covered 364 shares at a weighted average price of $33.2738 per share.

When did the reported 10x Genomics (TXG) insider sales by Shehnaaz Suliman take place?

The reported insider sales by director Shehnaaz Suliman took place on June 16, 2026. Both transactions involved open-market sales of Class A Common Stock and were later detailed in a Form 4 filing submitted to the Securities and Exchange Commission.

How were the sale prices for Shehnaaz Suliman’s 10x Genomics (TXG) transactions determined?

Each transaction was executed in multiple trades within stated price ranges, and the reported prices are weighted average sale prices. One ranged from $32.03 to $33.02, the other from $33.03 to $33.49, with full trade breakdowns available upon request.